Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation study of PF-3512676 in patients with metastatic or recurrent malignancies with stable disease or response
2004-003813-18Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2005
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of agatolimod in Non-hematologic malignancy and cancer, sponsored by Pfizer. Primary endpoints: Safety monitoring, Adverse events and 3 more. Started Sep 2005; status: completed.
02
Drugs
agatolimod
03
Conditions
Non-hematologic malignancycancer
Beyond the preview
Go deeper on 2004-003813-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003813-18.